共 50 条
- [42] Up to 6 years follow-up of patients receiving imatinib mesylate (Glivec) to treat unresectable or metastatic gastrointestinal stromal tumors (GISTs) EJC SUPPLEMENTS, 2007, 5 (04): : 404 - 404
- [43] Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan TRANSLATIONAL ONCOLOGY, 2011, 4 (06): : 328 - 335